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ABSTRACT Malignant hyperthermia (MH) and central core disease (CCD) are disorders of skeletal muscle Ca21 homeostasis
that are linked to mutations in the type 1 ryanodine receptor (RyR1). Certain RyR1 mutations result in an MH-selective
phenotype (MH-only), whereas others result in a mixed phenotype (MH 1 CCD). We characterized effects on Ca21 handling
and excitation-contraction (EC) coupling of MH-only and MH 1 CCD mutations in RyR1 after expression in skeletal myotubes
derived from RyR1-null (dyspedic) mice. Compared to wild-type RyR1-expressing myotubes, MH 1 CCD- and MH-only-
expressing myotubes exhibited voltage-gated Ca21 release (VGCR) that activated at more negative potentials and displayed
a signiﬁcantly higher incidence of spontaneous Ca21 oscillations. However, maximal VGCR was reduced only for MH 1 CCD
mutants (Y4795C, R2435L, and R2163H) in which spontaneous Ca21 oscillations occurred with signiﬁcantly longer duration
(Y4795C and R2435L) or higher frequency (R2163H). Notably, myotubes expressing these MH 1 CCD mutations in RyR1
exhibited both increased [Ca21]i and reduced sarcoplasmic reticulum (SR) Ca
21 content. We conclude that MH-only mutations
modestly increase basal release-channel activity in a manner insufﬁcient to alter net SR Ca21 content (‘‘compensated leak’’),
whereas the mixed MH 1 CCD phenotype arises from mutations that enhance basal activity to a level sufﬁcient to promote SR
Ca21 depletion, elevate [Ca21]i, and reduce maximal VGCR (‘‘decompensated leak’’).
INTRODUCTION
In skeletal muscle, excitation-contraction (EC) coupling
involves a unique, presumably physical interaction between
two different types of Ca21 channels: voltage-gated L-type
Ca21 channels (L-channels, dihydropyridine receptors
(DHPRs)) located in the sarcolemma and Ca21 release
channels (ryanodine receptors (RyR1s)) of the sarcoplasmic
reticulum (SR) (Melzer et al., 1995,). In response to sar-
colemmal depolarization, DHPRs undergo a conformational
change that activates nearby RyR1s. The subsequent massive
release of SR Ca21 into the myoplasm activates the con-
tractile machinery (a process termed ‘‘orthograde coupling’’)
(Nakai et al., 1996; Dulhunty et al., 2002). The DHPR-RyR1
mechanical interaction is bidirectional since RyR1 proteins
dramatically enhance the ability of the DHPR to function
efﬁciently as a Ca21-conducting ion channel (termed ‘‘retro-
grade coupling’’; Nakai et al., 1996; Grabner et al., 1999;
Avila and Dirksen, 2000; Dirksen, 2002).
Four clinically distinct hereditary human muscle disorders
are known to be associated with point mutations and deletions
in the gene encoding RyR1: malignant hyperthermia (MH),
central core disease (CCD), multiminicore disease (MmD),
and nemaline rod myopathy (NM) (for recent reviews, see
Jurkat-Rott et al., 2002; Taratuto, 2002; Lueck et al., 2004).
MH is a pharmacogenetic syndrome in which hyperthermia,
acidosis, hypermetabolism, and muscle rigidity are triggered
in MH-susceptible (MHS) individuals after exposure to
inhalation anesthetics (e.g., halothane) or depolarizing
skeletal muscle relaxants (e.g., succinylcholine). CCD, also
called Shy-Magee syndrome, is the ﬁrst described congenital
myopathy and is characterized by proximal muscle weakness
and skeletal deformities of the lower limbs (Taratuto, 2002;
Lueck et al., 2004). Diagnosis of CCD is determined through
histological identiﬁcation of single, large amorphous areas of
reduced oxidative enzyme activity in central or peripheral
regions of type 1 muscle ﬁbers (i.e., central cores). Mac-
Lennan and colleagues suggested that elevated resting Ca21
levels in CCD muscle may cause Ca21-mediated destruction
ofmitochondria in the center of themuscle ﬁber and that cores
represent a cellular defense mechanism designed to protect
the rest of the cell from further Ca21-induced damage (Loke
and MacLennan, 1998). However, in some CCD individuals,
cores are not centrally located, but rather are found in
peripheral regions of the muscle ﬁber. Additionally, resting
Ca21 levels are apparently not elevated by CCD mutations
that result in EC uncoupling (Avila et al., 2001, 2003b),
indicating that an elevation in resting Ca21 is not an absolute
requirement for core formation. Speciﬁc variants of MmD
(Ferreiro et al., 2002; Jungbluth et al., 2002) and NM
(Monnier et al., 2000; Scacheri et al., 2000) have very recently
been shown to be also associated with mutations in the RyR1
gene. Skeletal muscle biopsies of patients suffering from
MmD display multifocal, poorly circumscribed and short
core-like lesions, whereas skeletal muscle obtained from
individuals with NM exhibit rod-like structures when
visualized using Gomori’s trichrome stain in both type I and
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II skeletal muscle ﬁbers (Monnier et al., 2000; Scacheri et al.,
2000; Lueck et al., 2004).
Signiﬁcant clinical overlap exists between these related
muscle disorders. For example, early-stage CCD may ﬁrst
present as a minicore myopathy (Ferreiro et al., 2002), nema-
line rods have been found adjacent to central cores in biopsies
of someCCDpatients (Scacheri et al., 2000), andCCDpatients
are often found to be MHS. A particularly interesting example
of the clinical/genetic overlap between MH and CCD is the
ﬁnding that mutation of a single highly conserved arginine in
RyR1 to a cysteine residue (R2163C—all numbering here and
throughout corresponds to the rabbit RyR1 amino acid
sequence; accession P11716) results in MHS in the absence
of a clinical CCD phenotype in one family, whereas mutation
of the same amino acid to a histidine residue (R2163H) results
in MHS and CCD coincidence in another family (Manning
et al., 1998). For simplicity, in this report we refer to RyR1
mutations that result only in increasedMHSasMH-only,RyR1
mutations that result in CCD diagnosis in the absence of
a documented increase in MHS as CCD-only, and RyR1
mutations that result in the coincidence of MHS and clinical
CCD as MH1 CCD.
At least 61 different autosomal dominant mutations/
deletions in RyR1 are associated with MH and/or CCD (see
Dirksen and Avila, 2004, for review). Among these, at least
20 mutations result in MHS in the absence of clinical CCD
(i.e., MH-only) and only 10 mutations have been unequiv-
ocally shown to lead to a mixed MH and CCD phenotype
(i.e., MH 1 CCD). MH susceptibility has not been
conﬁrmed/tested for many of the other CCD mutations.
Parallel studies characterizing functional effects of RyR1
mutations associated with MH-only, CCD-only, and MH 1
CCD are required to probe possible distinct cellular/molec-
ular mechanisms associated with each disorder. Thus, we set
out to characterize the functional consequences of several
MH-only (R615C, R2163C, DE2347, and T4825I) and MH
1 CCD (R2163H, R2435L, T4636A, and Y4795C) muta-
tions in RyR1 on resting Ca21, SR Ca21 content, and the
orthograde/retrograde signals of EC coupling after expres-
sion in dyspedic myotubes. Our results indicate that the
R2163H, R2435L, and Y4795C MH 1 CCD mutations in
RyR1 lead to a parallel increase in resting myoplasmic Ca21
levels and decrease in SR Ca21 content, whereas MH-only
mutations do not signiﬁcantly alter these parameters. In
addition, maximal voltage-gated SR Ca21 release during EC
coupling is signiﬁcantly decreased only in MH 1 CCD-
expressing dyspedic myotubes. Interestingly, we also found
that both MH-only- and MH 1 CCD-expressing myotubes
exhibited spontaneous, nontriggered Ca21 oscillations.
However, myotubes expressing MH 1 CCD mutations in
RyR1 that result in steady-state SR Ca21 depletion exhibited
spontaneous Ca21 oscillations that occurred with signiﬁ-
cantly higher frequency (R2163H) or longer duration
(R2435L and Y4795C) than those observed for wild-type
(WT) RyR1-expressing myotubes. Our results suggest that
the MH 1 CCD mutations in RyR1 are unique in that they
enhance basal release-channel activity in a manner sufﬁcient
to promote steady-state SR Ca21 store depletion. Taken to-
gether, these ﬁndings indicate that MH and CCD coinci-
dence arises from a subgroup of MH mutations that exhibit
increased basal release-channel activity that leads to un-
compensated SR Ca21 unloading and a subsequent reduction
in voltage-gated Ca21 release during EC coupling.
METHODS
Preparation and cDNA microinjections of
dyspedic myotubes
Dyspedic myotubes were prepared as described previously (Avila and
Dirksen, 2000). Each of the human MH-only and MH 1 CCD mutations
used in this study were introduced into a rabbit RyR1 cDNA (accession
#X15750) using a standard two-step site-directed mutagenesis strategy
(Avila and Dirksen, 2001). The human MH/CCD amino acid mutations
(R614C, R2163H, R2163C, DE2347, R2435L, T4637A, Y4796C, and
T4826I—accession #J05200) investigated here correspond to R615C,
R2163H, R2163C, DE2347, R2435L, T4636A Y4795C, and T4825I,
respectively, in the rabbit RyR1 amino acid sequence (accession #P11716).
Four to 6 days after initial planting of myoblasts, nuclei of dyspedic
myotubes were microinjected with cDNAs encoding CD8 (0.2 mg/ml) and
the appropriate RyR1 expression plasmid (0.5 mg/ml). Expressing myotubes
were identiﬁed 2–4 days after cDNA microinjection after incubation with
CD8 antibody beads.
Intracellular Ca21 measurements in
intact myotubes
Intact (non-patch clamped) myotubes were loaded with the Ca21-sensitive
ratiometric dye Indo-1 AM (Molecular Probes, Eugene, OR) and resting
intracellular Ca21, as well as maximal responses to caffeine and cyclo-
piazonic acid (CPA) were measured as previously described (Avila et al.,
2001, 2003a). Brieﬂy, myotubes grown on glass coverslips were exposed for
45 min in rodent Ringer’s solution (see Recording solutions) containing 6
mM Indo-1 AM. Myotubes were then rinsed several times with Indo-1 AM-
free Ringer’s solution and incubated an additional 20 min at 37C to allow
for deesteriﬁcation of the dye. A small rectangular region of individual Indo-
1 AM-loaded expressing myotubes was excited at 350 nm using a DeltaRam
illumination system (Photon Technology International, Lawrenceville, NJ).
Fluorescence emission at 405 nm and 485 nm was monitored using a 403
(1.35 NA) oil immersion objective, collected with a photomultiplier
detection system, acquired at 100 Hz, and the results presented as the ratio
(R) of F405/F485. Resting ﬂuorescence ratio (Rbase) for each myotube was
converted to [Ca21]i using an in situ calibration approach described
previously (Avila et al., 2001). Brieﬂy, after recording the resting
ﬂuorescence ratio in Indo-1-AM-loaded myotubes, cells were whole-cell
patch-clamped with patch pipette solutions containing (in mM): 145 CsCl,
5 MgCl2, 10 BAPTA, 0–2.75 CaCl2, 10 HEPES, 0.006 K5Indo-1, pH 7.4.
Values of free Ca21 in the patch pipette ranged from 0–150 nM. After
equilibration with the pipette solution, a new ratio at the known free Ca21
level was then recorded. Multiple experiments at ﬁve different free Ca21
levels (0 nM, 30 nM, 90 nM, 120 nM, and 150 nM) were used to generate
a standard in situ resting Ca21 calibration curve. To measure SR Ca21
content, maximal concentrations of caffeine (10 mM) or cyclopiazonic acid
(CPA, 30 mM) were locally applied to myotubes using a rapid perfusion
system (Warner Instruments, Hamden, CT) that permits local application/
removal of agonists. Peak intracellular Ca21 responses to each agent are
expressed as DRatio (Ragonist  Rbase). Data were analyzed using FeliX
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(Photon Technology International, Lawrenceville, NJ) and SigmaPlot 2000
(SPSS, Chicago, IL) software packages. For the data presented in Figs. 1,
B–D, and 2, C–E, statistical signiﬁcance from WT RyR1 across multiple
groups was assessed using a one-way analysis of variance (ANOVA) and
a posthoc Dunnett test (P , 0.05). A chi-squared test was used to evaluate
the statistical signiﬁcance of effects of MH-only and MH1 CCD mutations
in RyR1 on the frequency of myotubes exhibiting spontaneous Ca21
oscillations (Fig. 2 B).
Simultaneous measurements of macroscopic
L-currents and Ca21 transients
The whole-cell patch-clamp technique (Hamill et al., 1981) in conjunction
with a Ca21-sensitive dye (ﬂuo-3) was used to simultaneously measure
voltage-gated L-currents and intracellular Ca21 transients in RyR1-, MH-
only-, and MH 1 CCD-expressing myotubes. A 1-s prepulse to 20 mV
delivered immediately before each test pulse was used to inactivate sodium
and T-type Ca21 channels without producing signiﬁcant L-channel in-
activation. L-currents were subsequently elicited by brief (30-ms) test depo-
larizations applied from a holding potential of –80 mV. Capacitative currents
were minimized to ;10% using the capacitance cancellation feature of the
patch-clamp ampliﬁer. Remaining linear components were leak-subtracted
using P/3 protocol delivered from the holding potential before each test
pulse. Peak L-currents were normalized to total cell capacitance (pA/pF),
plotted as a function of test potential, and ﬁtted according to the following
Boltzmann equation:
I ¼ Gmax ðVm  VrevÞ=f11 exp½ðVG1=2  VmÞ=kGg; (1)
where Gmax is maximal L-channel conductance, Vm is the test potential, Vrev
is the extrapolated reversal potential, VG1/2 is the potential for half-maximal
activation of Gmax, and kG is a slope factor. Relative changes in intracellular
Ca21 during each test pulse were recorded in ﬂuo-3 dialyzed myotubes as
described previously (Avila et al., 2003a). All patch-clamp experiments
were carried out after allowing an ;5-min period of dialysis after
establishment of the whole-cell conﬁguration. Fluo-3-dialyzed myotubes
were excited at 480 nm and ﬂuorescence emission measured at 535 nm was
analog ﬁltered (t ¼ 0.5 ms) before digitization at 10 kHz. A computer-
controlled shutter was used to eliminate dye illumination during intervals
between test pulses. Relative changes in Ca21 were expressed as DF/F
([Fpeak – Fbase]/Fbase) at the end of each test pulse, plotted as a function of
Vm, and ﬁtted according to:
DF=F ¼ ðDF=FÞmax=f11 exp½ðVF1=2  VmÞ=kFg; (2)
where (DF/F)max is the maximal ﬂuorescence change, VF1/2 is the potential
for half-maximal activation of (DF/F)max, and kF is a slope factor. Pooled
current-voltage (I-V) and ﬂuorescence-voltage (DF/F-V) data in Table 1
were expressed as mean 6 SE. Statistical signiﬁcance from WT RyR1-
expressing myotubes was determined using a Student’s two-tailed t-test. For
all analyses, differences were considered statistically signiﬁcant at P, 0.05.
Recording solutions
Myoplasmic Ca21 levels in intact myotubes were determined in the presence
of a normal rodent Ringer’s solution consisting of (in mM): 145 NaCl, 5
KCl, 2 CaCl2, 1 MgCl2, and 10 HEPES. For patch-clamp experiments, the
FIGURE 1 MH 1 CCD mutations in RyR1 induce parallel and opposing changes in resting Ca21 and releasable SR Ca21 content. (A) Representative
caffeine-induced Ca21 responses obtained from intact Indo-1 AM-loaded dyspedic myotubes expressingWT RyR1, R2163H (MH1 CCD), or R2163C (MH-
only). Intracellular Ca21 levels were recorded in the absence (resting Ca21) and presence of 10 mM caffeine (shaded bar). For each panel, a dashed line
representing the average resting ﬂuorescence ratio for WT RyR1-expressing myotubes is shown for comparison. (B) Average resting Ca21 levels for dyspedic
myotubes expressing either WT RyR1 (black bar), four different MH1 CCD mutant RyR1s (shaded bars), and four different MH-only mutant RyR1s (white
bars). Number of experiments is given above each bar. (C andD) Average peak responses to application of maximal concentrations of caffeine (C, 10 mM) and
CPA (D, 30 mM) in dyspedic myotubes expressing wild-type RyR1 (black bar) and each of the MH 1 CCD (shaded bars) and MH-only (white bars)
mutations in RyR1 illustrated in B. A one-way ANOVA analysis (p, 0.05) revealed that meanWT RyR1 data in B–Dwere statistically indistinguishable from
the corresponding MH-only group data, whereas MH 1 CCD group data were statistically different from both WT RyR1 and MH-only group data. Asterisks
indicate signiﬁcant differences compared to WT RyR1 using ANOVA/Dunnett analysis (P , 0.05). In this and subsequent ﬁgures, RyR1 mutants for each
group (MH 1 CCD and MH-only) are presented in increasing order for elevating resting Ca21 as shown in B.
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bath solution contained (in mM) 145 TEA-Cl, 10 CaCl2, and 10 HEPES and
the internal solution contained (in mM) 145 Cs-aspartate, 10 CsCl, 0.1
Cs2EGTA, 1.2 MgCl2, 5 Mg-ATP, 0.2 K5-ﬂuo-3, and 10 HEPES. The pH of
all solutions was adjusted to 7.4.
RESULTS
Only MH 1 CCD mutations in RyR1 increase
resting Ca21 and promote SR Ca21 depletion
We have previously shown that dyspedic myotubes express-
ing certain MH 1 CCD mutations in RyR1 exhibit reduced
voltage-gated SRCa21 release as a result of a partial depletion
of SR Ca21 content (Avila and Dirksen, 2001; Dirksen and
Avila, 2002; Avila et al., 2003b). Interestingly, Tong et al.
(1999) found that the Ca21 content of the endoplasmic
reticulum was reduced after transient expression of both MH-
only and MH1 CCDmutations in MH/CCD regions 1 and 2
in HEK-293 cells. To determine if a similar effect on SRCa21
store content occurs after expression within a skeletal muscle
context, we compared the functional consequences (on
resting Ca21 and SR Ca21 content) of Indo-1 AM-loaded
dyspedic myotubes expressing several different MH-only
(R615C, R2163C, DE2347, and T4825I) and MH 1 CCD
(R2163H, R2435L, T4636A, and Y4795C) mutant RyR1
proteins (Fig. 1). In these experiments, releasable SR Ca21
content was measured following exposure to maximal
concentrations of either 10 mM caffeine (which rapidly
releases SRCa21 by directly activating RyRs) or 30mMCPA
(which increases cytoplasmic Ca21 by inhibiting SR Ca21-
ATPase activity and thereby preventing Ca21 reuptake lost
through passive Ca21 leak pathways). Together, caffeine and
CPA experiments provide twomechanistically distinct means
of assessing SR Ca21 content in WT-, MH-only-, and MH1
CCD-expressing myotubes. In this regard, mutations to
R2163 of RyR1 are of particular comparative interest as
substitution by a histidine residue at this position results in an
FIGURE 2 MH-only- and MH 1 CCD-
expressing dyspedic myotubes exhibit in-
creased incidence of spontaneous ﬂuctuations
in intracellular Ca21 (Ca21 oscillations). (A)
Representative spontaneous Ca21 oscillations
in intact Indo-1 AM-loaded myotubes express-
ing WT RyR1 (top) and each of the eight
different MH 1 CCD (left) and MH-only
mutants (right). For comparison, a dashed line
representing the average resting ﬂuorescence
ratio for WT RyR1-expressing myotubes is
shown for each construct. (B) Global intracel-
lular Ca21 levels were continuously recorded
for all of the cells analyzed in Fig. 1 B and
spontaneous Ca21 oscillations were analyzed
for the percentage of myotubes exhibiting Ca21
oscillations during the ﬁrst 60 s of recording
(numbers above each bar represent the number
of myotubes from Fig. 1 B that exhibited
spontaneous oscillations for each construct).
Statistical signiﬁcance in the percentage MH1
CCD- and MH-only-expressing myotubes ex-
hibiting spontaneous Ca21 oscillations com-
pared to that of WT RyR1-expressing
myotubes was assessed using a nonparametric
chi-squared test (*p , 0.05, pp , 0.1). (C–E)
Spontaneous Ca21 oscillation amplitude (C),
duration (D), and frequency (E) analyzed from
WT RyR1-, MH 1 CCD-, and MH-only-
expressing myotubes. Asterisks indicate sig-
niﬁcant differences compared to RyR1 using
ANOVA/Dunnett analysis (P , 0.05). MH/
CCD mutations signiﬁcantly increased the
duration (Y4795C and R2435L) and frequency
(R2163H) of spontaneous Ca21 oscillations,
whereas both MH-only and MH/CCD muta-
tions in R2163 (R2163C and R2163H) resulted
in a signiﬁcant reduction in Ca21 oscillation
amplitude.
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MH 1 CCD phenotype, whereas a cysteine mutation of the
same residue results in anMH-selective phenotype (Manning
et al., 1998).
As reﬂected in the representative traces shown in Fig. 1 A,
compared to wild-type RyR1-expressing myotubes (left),
resting Ca21 was elevated and maximal caffeine-induced
Ca21 release was reduced in R2163H-expressing (MH 1
CCD) myotubes (middle). However, myotubes expressing an
MH-only mutation of the same residue (R2163C) were with-
out effect on either resting Ca21 or maximal caffeine-induced
Ca21 release (right). On average, the R2163H mutation
signiﬁcantly increased resting Ca21 from ;50 nM (RyR1, n
¼ 143) to;90 nM (R2163H, n¼ 49), whereas resting Ca21
was not signiﬁcantly altered in R2163C-expressingmyotubes
(R2163C, n ¼ 49) (Fig. 1 B). In addition, average maximal
caffeine- (10 mM, Fig. 1C) and CPA-induced (30mM, Fig. 1
D) responses were signiﬁcantly reduced in R2163H-express-
ing, but not R2163C-expressing, myotubes. These results are
striking in that mutation of a single RyR1 residue associated
with CCD (R2163H) increased resting Ca21 and reduced
caffeine and CPA responses, whereas these parameters were
essentially unaffected by an MH-only mutation of the same
residue (R2163C). Accordingly, two of the other MH1CCD
mutations tested (R2435L and Y4795C) also signiﬁcantly
increased resting Ca21 levels and reduced maximal caffeine
andCPA responses. In contrast, none of theMH-onlymutants
tested (T4825I, R615C, DE2347, and R2163C) signiﬁcantly
modiﬁed either resting Ca21 or maximal caffeine/CPA
responses (Fig. 1, B–D).
MH-only- and MH 1 CCD-expressing myotubes
exhibit increased incidence of spontaneous
Ca21 oscillations
During the course of these experiments, we noted that MH-
only- and MH 1 CCD-expressing myotubes exhibited
a signiﬁcant degree of spontaneous, slow ﬂuctuations in
intracellular Ca21 (i.e., Ca21 oscillations). Thus, we com-
pared the properties (incidence, peak amplitude, duration, and
frequency) of spontaneous Ca21 oscillations for dyspedic
myotubes expressing WT RyR1, MH 1 CCD mutant RyR1
proteins, and MH-only mutant RyR1 proteins (Fig. 2).
Representative spontaneous Ca21 oscillations recorded from
dyspedic myotubes expressing WT RyR1 and each of the
eight different disease mutations in RyR1 are shown in Fig. 2
A. Compared to RyR1, the proportion of myotubes exhibiting
spontaneous Ca21 oscillations within the ﬁrst 60 s of
recording was higher for most of the MH-only (T4825I,
R615C, and R2163C) and MH 1 CCD (T4636A, Y4795C,
R2435L, and R2163H) mutants (Fig. 2 B). Speciﬁcally,
spontaneous Ca21 oscillations were observed in only 7 out of
143 WT RyR1-expressing myotubes (;5%). A higher
incidence of spontaneous Ca21 oscillations (ranging from
15 to 82%) was observed for all of the different disease
mutations in RyR1, except DE2347 (6%; 1 out of 17). Fig. 2
also summarizes the effects of MH-only and MH 1 CCD
mutations in RyR1 on the amplitude (Fig. 2C), duration (Fig.
2 D), and frequency (Fig. 2 E) of spontaneous Ca21
oscillations.
Interestingly, mutations to residue R2163 were unique in
that signiﬁcant decreases in the amplitude of spontaneous
Ca21 oscillations were observed for both R2163H- (MH 1
CCD) and R2163C-expressing (MH-only) myotubes (Fig. 2
C). Importantly,MH/CCDmutationswere the onlymutations
that caused a signiﬁcant alteration in either the duration
(Y4795C and R2435L) or frequency (R2163H) of spontane-
ous Ca21 oscillations duration compared to that of WT RyR1
(Fig. 2, D–E). Taken together, the results from Fig. 2 suggest
that theMH1CCDmutations in RyR1 promote spontaneous
Ca21 oscillations that last signiﬁcantly longer (e.g., Y4795C
and R2435L; Fig. 2 D) or occur at a much higher frequency
(e.g., R2163H; Fig. 2 E) than those attributable to WT RyR1.
Thus, the increased incidence, duration, and frequency of
nontriggered activity of the MH 1 CCD mutant release
channels likely contributes to the steady-state depletion of SR
Ca21 content observed for these mutants (Fig. 1).
TABLE 1 Parameters of ﬁtted I - V and DF/F - V curves
I - V data DF/F - V data
n Gmax VG1/2 kG Vrev (DF/F)max VF1/2 kF
ns/nF mV mV mV mV mV
RyR-1 31 193 6 14 15.6 6 0.7 5.6 6 0.1 75 6 1.0 2.9 6 0.3 7.5 6 1.0 5.6 6 0.3
MH1CCD
T4636A 10 198 6 18 16.6 6 1.5 6.2 6 0.2 76 6 1.7 2.2 6 0.4 3.4 6 2.4 4.6 6 0.6
Y4795C 9 229 6 41 15.4 6 1.1 *6.6 6 0.2 75 6 1.3 *1.6 6 0.2 *7.0 6 1.9 7.1 6 0.3
R2435L 8 213 6 29 17.7 6 1.8 5.9 6 0.2 72 6 2.5 2.0 6 0.4 *0.7 6 1.5 4.9 6 0.3
R2163H 8 144 6 18 *8.6 6 1.5 *7.5 6 0.3 75 6 2.1 *1.6 6 0.7 *13.5 6 1.1 6.8 6 1.7
MHonly
T4825l 13 180 6 19 *19.4 6 1.7 *6.4 6 0.2 78 6 2.3 2.4 6 0.3 5.1 6 2.0 4.5 6 0.4
R615C 9 188 6 15 13.9 6 1.3 *6.6 6 0.4 72 6 1.7 3.3 6 1.0 *0.1 6 1.6 5.2 6 0.8
DE2347 9 231 6 20 13.4 6 1.1 *6.4 6 0.1 74 6 2.4 3.1 6 0.7 *3.8 6 1.7 5.0 6 0.4
R2163C 14 167 6 14 12.8 6 1.1 *7.2 6 0.2 74 6 1.1 3.1 6 0.3 *7.0 6 1.5 5.5 6 0.2
*Compared to RyR-1 p , 0.05.
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Effects of MH-only and MH 1 CCD mutations on
bidirectional DHPR-RyR1 mechanical coupling
We have previously shown that CCD mutations in MH/CCD
regions 1 and 2 promote parallel reductions in SR Ca21
content, maximal voltage-gated SR Ca21 release, and the
voltage required for half-maximal Ca21 release (Avila and
Dirksen, 2001; Dirksen and Avila, 2002; Avila et al., 2003b).
Since the data shown in Fig. 1 suggest that store depletion
occurs only for MH1 CCDmutations in RyR1 and not MH-
only mutations, we compared the magnitude and sensitivity
of voltage-gated SR Ca21 release in MH 1 CCD- and MH-
only-expressing myotubes. To accomplish this goal, we
simultaneously monitored macroscopic L-type Ca21 cur-
rents (L-currents) and voltage-gated Ca21 transients in
whole-cell voltage-clamp experiments. Fig. 3, A and B,
demonstrates that L-current magnitude, kinetics, and voltage
dependence are similar for WT RyR1- (black circles),
R2163H- (shaded circles), and R2163C-expressing (open
circles) myotubes. No signiﬁcant differences in maximal
L-channel conductance were found between these or any of
the nine different RyR1 constructs (Fig. 3 C; see also Table
1). Moreover, the few differences observed in the voltage
dependence of L-channel activation (VG1/2, and kG) were
modest in magnitude and did not reﬂect any ordered or
systematic dependence (Table 1). Thus, all of the different
MH-only and MH1 CCD mutant RyR1 proteins augmented
DHPR L-channel activity to a similar degree (i.e., support
retrograde coupling), results which demonstrate that the
mutant release channels are synthesized, targeted to SR-
sarcolemmal release sites, and functionally interact with
junctional voltage sensors.
Although retrograde coupling was not signiﬁcantly altered
by MH-only and MH 1 CCD mutations in RyR1 (Fig. 3),
signiﬁcant effects on orthograde coupling were observed
(Fig. 4). Fig. 4 A shows representative voltage-gated Ca21
transients elicited by 30-ms voltage steps to the indicated
potentials (left) in dyspedic myotubes expressing either RyR1
(black circles), R2163H (shaded circles), or R2163C (open
circles). These data demonstrate that mutation of R2163 to
either a histidine or cysteine residue results in a similar
hyperpolarizing shift in the threshold for voltage-gated SR
Ca21 release (i.e., in Fig. 4 A detectable release occurs at –20
mV for both R2163H and R2163C, but not WT RyR1).
However, maximal voltage-gated SR Ca21 release was
signiﬁcantly reduced only in R2163H-expressing myotubes.
Thus, although bothmutations caused a similar increase in the
sensitivity to activation by voltage, maximal voltage-gated
Ca21 release was signiﬁcantly reduced only for the MH 1
CCDmutation in R2163. On average, maximal voltage-gated
SR Ca21 release (DF/F)max was reduced 45% in R2163H-
expressingmyotubes (Fig. 4,B andC; see also Table 1). These
FIGURE 3 The MH 1 CCD and MH-only
mutations in RyR1 fully restore retrograde
coupling with sarcolemmal DHPRs. (A) Rep-
resentative whole-cell L-type Ca21 currents
recorded from RyR1- (left), R2163H- (middle),
and R2163C-expressing (right) dyspedic my-
otubes. Current traces were elicited in response
to brief (30-ms) membrane depolarizations to
the indicated membrane potentials. Dashed
lines represent the zero current level. (B)
Average (6SEM) peak current-voltage (I-V)
relationships for dyspedic myotubes expressing
wild-type RyR1 (black circles; n ¼ 31),
R2163H (shaded circles, top; n ¼ 8), and
R2163C (open circles, bottom; n ¼ 14). The
average values (6SEM) for the parameters
obtained by ﬁtting each myotube within a group
separately to Eq. 1 are given in Table 1 (I-V
data). The solid lines through the data were
obtained using Eq. 1 and the corresponding
parameters given in Table 1 (I-V data). (C)
Comparison of maximal L-channel conduc-
tance (Gmax) obtained from RyR1- (black bar),
MH 1 CCD- (shaded bars), and MH-only-
expressing (white bars) myotubes. Number of
experiments is given above each bar.
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results demonstrate that although both mutations in residue
R2163 enhance the inherent voltage sensitivity of the Ca21
releasemechanism, theMH1CCDmutation is unique in also
causing a reduction in the maximum magnitude of voltage-
gated release. Accordingly, maximal voltage-gated release
was reduced to a similar degree inY4795C-expressing
myotubes (and to a lesser degree in R2435L-expressing
myotubes), but was essentially unaltered in myotubes
expressing MH-only mutations in RyR1 (Fig. 4 C and Table
1). Furthermore, the voltage sensitivity of Ca21 release
mechanism (VF1/2) was signiﬁcantly reduced by most (six out
of eight) of the MH1 CCD andMH-only mutations in RyR1
(Fig. 4 D and Table 1). Taken together, the results of Fig. 4
indicate that increased release-channel sensitivity to activa-
tion by voltage correlates with increased MH susceptibility,
whereas a reduction in the magnitude of voltage-gated SR
Ca21 release represents a unique distinguishing feature of the
CCD phenotype.
DISCUSSION
This study presents the ﬁrst direct comparison of the
functional effects on skeletal muscle Ca21 homeostasis and
orthograde/retrograde DHPR/RyR1 coupling of mutations in
RyR1 that result in either an MH-selective phenotype or the
coincidence of both MH and CCD. Our results demonstrate
that MH-only and MH 1 CCD mutant RyR1 proteins fully
support retrograde coupling with sarcolemmal DHPRs (as
indicated by normal RyR1-mediated restoration of maximal
L-channel conductance or Gmax, Fig. 3 and Table 1).
However, compared to WT RyR1-expressing myotubes,
MH-only- andMH1CCD-expressingmyotubes exhibit both
an increased incidence of nonevoked or spontaneous Ca21
oscillations (Fig. 2) and enhanced sensitivity of the voltage-
gated Ca21 release mechanism (i.e., a hyperpolarized shift in
VF1/2, Fig. 4 and Table 1). Importantly, the MH 1 CCD
mutations in RyR1 differed from MH-only mutations in
several important aspects in that onlyMH1CCD-expressing
myotubes also exhibited 1), elevated resting Ca21 levels; 2),
a reduction in maximal caffeine/CPA-induced Ca21 release;
3), altered duration/frequency of spontaneous Ca21 oscil-
lations; and 4), a reduction in the magnitude of maximal
voltage-gated SR Ca21 release. A similar rank order for MH
1 CCD mutations in RyR1 was observed for elevations in
resting Ca21 (R2163H. Y4795C, R2435L. T4636A; Fig.
1 B), SR Ca21 depletion (R2163H . Y4795C, R2435L .
T4636A; Fig. 1, C and D), and reduced voltage-gated Ca21
release (R2163H, Y4795C. R2435L. T4636A; Fig. 4 C).
These results suggest that SR Ca21 unloading underlies the
observed reduction in Ca21 release during EC coupling in
FIGURE 4 Voltage-gated SR Ca21 release
is preferentially reduced in MH 1 CCD-
expressing myotubes. (A) Representative in-
tracellular Ca21 transients elicited by 30-ms
test pulses to the indicated potentials. Repre-
sentative Ca21 transients are displayed for
dyspedic myotubes expressing RyR1 (left),
R2163H (middle), and R2163C (right). Dashed
lines represent basal ﬂuorescence before de-
polarization. (B) Average voltage-dependence
of intracellular Ca21 transients (measured at
the end of each test pulse) for dyspedic
myotubes expressing wild-type RyR1 (black
circles; n ¼ 31), R2163H (shaded circles, top;
n ¼ 8), and R2163C (open circles, bottom;
n ¼ 14). The average values (6SEM) for the
parameters obtained by ﬁtting each myotube
within a group separately to Eq. 2 are given in
Table 1 (DF/F-V data). The solid lines through
the data were obtained using Eq. 2 and the
corresponding parameters given in Table 1
(DF/F-V data). For clarity, average values
(6SEM) for maximal voltage-gated SR Ca21
release ([DF/F]max) and the voltage required for
half-maximal activation of release (VF1/2) for
WT RyR1 (black bar/symbol), MH 1 CCD
mutant RyR1s (shaded bars/symbols), and
MH-only mutant RyR1s (white bars/symbols)
are plotted in C and D, respectively. Dashed
lines in C and D correspond to mean data for
WT RyR1. *p , 0.05, pp , 0.1 compared to
RyR1.
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MH 1 CCD-expressing myotubes. In agreement with this
notion, resting Ca21 levels, releasable SR Ca21 content, and
maximal voltage-gated SR Ca21 were all unaltered in MH-
only-expressing myotubes. Taken together, our results in-
dicate that SRCa21 depletion and increased basal Ca21 levels
are preferentially associated with RyR1 mutations that result
in MH and CCD coincidence.
Distinct alterations in Ca21 handling caused by
MH-only and MH 1 CCD mutations in RyR1
Anumber of results presented here and elsewhere (Tong et al.,
1999; Avila and Dirksen, 2001; Avila et al., 2003b) indicate
that certain CCD mutations in RyR1 (including R164C,
Y523S, R2163H, R2435H, R2435L, and Y4795C) promote
SR/ER Ca21 depletion. First, compared to wild-type RyR1-
expressing cells, the magnitude of Ca21 release in response to
application of maximal concentrations of caffeine is reduced
after both heterologous (Tong et al., 1999) and homologous
expression of these CCD mutant RyR1 proteins (Avila and
Dirksen, 2001; Avila et al., 2003b; Fig. 1, A and C). Second,
since mutations in RyR1 could alter caffeine-induced Ca21
release via a mechanism distinct from a change in SR Ca21
load, we also assessed SR Ca21 load using CPA (Avila and
Dirksen, 2001; Avila et al., 2003b; Fig. 1 D), an agent that
increasesmyoplasmicCa21 in amanner independent ofRyR1
activation (Inesi and Sagara, 1994). The reduced CPA
responses of MH 1 CCD-expressing myotubes (but not
MH-only-expressing myotubes) provides further evidence
that MH 1 CCD mutations in RyR1 preferentially promote
signiﬁcant SR Ca21 unloading (Fig. 1 D). Third, we recently
demonstrated that SR Ca21 depletion of Y523S-expressing
myotubes is abolished after incorporation of an additional
mutation in the RyR1 pore region (I4897T) that renders the
channel poorly permeable to Ca21 (Avila et al., 2003b).
Finally, control experiments in normal myotubes indicate that
caffeine and CPA operate on identical Ca21 storage compart-
ments since CPA does not alter myoplasmic Ca21 levels after
the application of a maximal concentration of caffeine (data
not shown). Taken together, these results provide compelling
evidence that MH 1 CCD mutations in RyR1 are unique in
promoting a signiﬁcant reduction in steady-state SR Ca21
load.
The putative impact of MH-only mutations in RyR1 on
resting myoplasmic Ca21 remains controversial (Mickelson
andLouis, 1996). Conﬂicting reports thatMH-onlymutations
either increase (e.g., Lopez et al., 1986, Wehner et al., 2002)
or exert no effect on (Iaizzo et al., 1988; Censier et al., 1998;
Tong et al., 1999; this study) resting Ca21 levels may arise
from differences in the methodologies used to quantify
intracellular Ca21 (e.g., Ca21-sensitive intracellular micro-
electrodes versus Ca21-sensitive ﬂuorescence dyes). Another
potential source of variation in these studies is the biological
background used to investigate the mutant SR Ca21 release
channels (e.g., native cells versus heterologous or homolo-
gous expression systems). However, it is well established that
intracellular Ca21 levels are signiﬁcantly elevated by certain
MH1 CCDmutations in RyR1 (Tong et al., 1999; Avila and
Dirksen, 2001; Avila et al., 2003b; Fig. 1 B). In this context,
our experiments in which resting Ca21 levels were compared
using a single assay conducted under identical conditions in
the context of a uniform muscle expression system provide
strong support for the notion that MH 1 CCD mutations in
RyR1 produce a more profound alteration in resting Ca21
than that observed for MH-only mutations.
Potential limitations of estimations in resting Ca21
As discussed above, a difference in methodologies used to
estimate resting Ca21 (i.e., Ca21-sensitive microelectrodes
versus Ca21-sensitive ﬂuorescence dyes) likely contributes to
the current controversy as to the effects ofMH-onlymutations
in RyR1 on intracellular Ca21 levels. Unfortunately,
a signiﬁcant number of limitations/assumptions are associ-
ated with both experimental approaches (Takahashi et al.,
1999).Wemonitored restingCa21 levels using a ﬂuorescence
approach that does not exhibit the temporal limitations and
potential for impalement-induced sarcolemmal damage that
can occur when using ion-sensitive intracellular micro-
electrodes. Nevertheless, a number of other limitations/
assumptions are associated with our indo-1 measurements
of resting Ca21. For example, since the Ca21 afﬁnity (i.e.,Kd)
and the ﬂuorescence spectra of Indo-1 are inﬂuenced by
relatively small changes in pH (Baker et al., 1994), differences
in intracellular pH (pHi) ofWT-,MH-only-, andMH1CCD-
expressing myotubes could confound the accuracy of our
intracellular Ca21 measurements. Additionally, changes in
the cellular redox state resulting from expression of MH-only
and/or MH1CCDmutant RyR1 proteins could also alter the
properties of indo-1 and/or autoﬂuorescence of a redox-
sensitive cellular constituent (e.g., NADH, which is also
excited at 350 nm; Shorte and Bolsover, 1999; Takahashi
et al., 1999). Finally, by virtue of its Ca21 chelator activity,
high-afﬁnity Ca21 indicators like indo-1 may buffer small
changes in myoplasmic Ca21 when loaded into myotubes at
high concentrations.
In addition to potential direct effects on the properties of
indo-1, changes in the levels of important myoplasmic
constituents (e.g., pH, ATP, glutathione) caused byMH-only
and/or MH 1 CCD mutations in RyR1 could indirectly in-
ﬂuence myoplasmic Ca21 by altering regulation of RyR1
activity (for a recent review see Fill and Copello, 2002). Thus,
it is difﬁcult to distinguish between direct effects of disease
mutations on RyR1 function and alterations in RyR1
regulation that are secondary to changes in myoplasmic
pHi, redox, and/or ATP levels. Consequently, observed
differences in resting indo-1 ﬂuorescence could reﬂect
alterations in one or more of these myoplasmic factors rather
than a genuine change in resting free Ca21 per se. Moreover,
dialysis with a uniform internal solution during our in situ
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calibration procedure would tend to eliminate differences
resulting from changes in these factors. Clearly, future work
will be needed (e.g., studies that combine the strengths of both
Ca21-sensitive microelectrode and ﬂuorescence approaches)
before a deﬁnitive conclusion can be made with regard to the
inﬂuence of MH-only mutations in RyR1 on resting Ca21
levels in skeletal muscle.
Pathophysiological implications
How might mutations in RyR1 result in release-channel
hypersensitivity and malignant hyperthermia susceptibility
(MH-only), whereas other RyR1 mutations promote the
coincidence of MHS with muscle weakness and the develop-
ment of central cores (MH1 CCD)? Our results suggest that
this dichotomy might arise from fundamentally distinct
changes in SR Ca21 release-channel function induced by
MH-only and MH 1 CCD mutations in RyR1. Fig. 5
summarizes one possible means by which distinct functional
defects in Ca21 handling and EC coupling observed in this
study might result in phenotype-speciﬁc manifestations of
MH and CCD.
Our ﬁndings, along with those of others (Tong et al., 1997,
1999;Dietze et al., 2000;Avila andDirksen, 2001;Yang et al.,
2003), suggest that bothMH-only andMH1CCDmutations
in RyR1 cause release channels to exhibit increased/over-
active basal channel activity and enhanced sensitivity to
activation by both endogenous (i.e., voltage sensors) and
exogenous (e.g., caffeine, halothane, 4-chloro-m-cresol)
RyR1 triggering agents. However, results presented here
suggest that increased release-channel activity/sensitivity
resulting fromMH-onlymutations in RyR1 are subtle enough
that cellular compensatory mechanisms (e.g., enhanced SR
Ca21 reuptake via increased sarco/endoplasmic reticulum
Ca21 pump expression/activity) are sufﬁcient to ensure
maintenance of normal SR Ca21 content and voltage-gated
SR Ca21 release during EC coupling (termed Compensated
leak in Fig. 5). On the other hand, MH 1 CCD mutations in
RyR1 exhibit a greater degree of increased basal activity (i.e.,
increased duration or frequency of spontaneous Ca21
oscillations) that are severe enough that compensatory
mechanisms are unable to prevent partial steady-state SR
Ca21 store depletion and a subsequent reduction in the
magnitude of Ca21 release during EC coupling (termed
Decompensated leak in Fig. 5). Under this scenario, MH 1
CCD mutations in RyR1 represent an extreme example of
release-channel hyperactivity that leads to net SR Ca21
unloading. We must emphasize, however, that the scheme
depicted in Fig. 5 is an extrapolation of our experimental
results and represents only one view of how our data could be
interpreted within the clinical context of MH and CCD.
We have previously suggested that mutations in the pore-
lining region of RyR1 reduce Ca21 release during EC
coupling in a manner that does not arise from increased basal
release-channel activity or SR Ca21 unloading, but rather by
reducing the gating and/or Ca21 permeation of activated
release channels (termed ‘‘EC uncoupled’’ in Fig. 5) (Avila
et al., 2001, 2003b). Consequently, the EC uncoupling
mechanism would not be expected to result in increased MH
susceptibility (i.e., CCD-only; Fig. 5). Consistent with this
prediction, no anesthetic complications were noted after
exposure to MH-triggering anesthetics for 19 CCD-related
FIGURE 5 Schematic depicting fundamen-
tally distinct cellular consequences of muta-
tions in RyR1 that result in MH-only
(compensated leak), MH 1 CCD (decompen-
sated leak), and CCD-only (EC uncoupled)
mutations in RyR1. In this scheme, MH in the
absence of CCD arises from RyR1 mutations
that result in overactive/supersensitive release
channels that fail to cause a net change in
steady-state SR Ca21 content (compensated
leak), but predispose muscle to increasedMHS
upon exposure to triggering agents. The
primary distinguishing feature of CCD muta-
tions is a reduction in maximal voltage-gated
release that results either from a net reduction
in steady-state SR Ca21 content or EC
uncoupling (functional uncoupling of depolar-
ization from the release of Ca21 from a full SR
store). MH and CCD coincidence occurs for
mutations in RyR1 that enhance RyR1 acti-
vity/sensitivity to an extent sufﬁcient to result
in a partial depletion of SR Ca21 stores
decompensated leak).
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individuals possessing the I4898Tmutation in the pore-lining
region of the channel (Lynch et al., 1999).
SR Ca21 depletion does not result from
increased sensitivity to activation by voltage
Voltage-clamp experiments from our laboratory have re-
vealed that certain MH 1 CCD mutations in RyR1 (R164C,
Y523S, R2163H, R2435H, R2435L, and Y4795C) signiﬁ-
cantly enhance release-channel sensitivity to activation by
voltage (Avila and Dirksen, 2001; Avila et al., 2003b; this
report). Interestingly, six of the eight diseasemutants in RyR1
investigated in this study (MH-only: R614C, R2163C, and
DE2347; MH 1 CCD: R2163H, R2435L, and Y4796C)
exhibited varying degrees (7–21 mV hyperpolarizing shift in
VF1/2) of increased sensitivity to activation by the voltage
sensor (Fig. 4 and Table 1). Consistent with these data, an
increased sensitivity of voltage-gated SR Ca21 release at-
tributable to the porcine R615C MH-selective mutation in
RyR1 is also well-documented (Gallant and Lentz, 1992;
Gallant and Jordan, 1996; Dietze et al., 2000). Additionally,
Yang et al. (2003) recently found that KCl-stimulated Ca21
release occurred at lower concentrations of KCl in dyspedic
myotubes expressing seven different MH mutations in RyR1
(R164C, G342R, R615C, R2163C, V2168M, R2458H, and
T4825I), four of which were also studied here (R164C,
R615C, R2163C, and T4825I). Thus, it is clear that the
voltage sensitivity of theCa21 releasemechanism is increased
by both MH-only and MH 1 CCD mutations in RyR1. A
similar ﬁnding was recently reported for a novel MH-causing
mutation in the III-IV linker of the skeletal muscle DHPR
(R1086H) (Weiss et al., 2004).
Yang et al. (2003) also found that compared to WT RyR1,
dyspedic myotubes expressing MH mutants exhibited
reduced SR Ca21 release in response to maximal concen-
trations of direct channel activators (i.e., caffeine and 4-
chloro-m-cresol) and a paradoxical increase in Ca21 release
in response to 60 mM KCl depolarization. These results are
in contrast to our observations that neither maximal caffeine-
induced Ca21 release (Fig. 1 C) nor maximal voltage-gated
Ca21 release (Fig. 4 C and Table 1) was signiﬁcantly altered
after expression in dyspedic myotubes of four different MH-
only mutant RyR1 proteins (R615C, R2163C, DE2347, and
T4825I). One possible explanation for this discrepancy is
that the study of Yang et al. (2003) inferred effects on
maximal orthograde coupling based on 10-s applications of
a high concentration (60 mM) of extracellular KCl. In
addition, activation of SR Ca21 release after transient
application of 60 mM KCl was apparently not sufﬁcient to
provide a saturating response (see Fig. 2 in Yang et al.,
2003). The use of saturating KCl concentrations in these
experiments is important since as voltage-gated Ca21 release
is shifted to more negative potentials for MH-expressing
myotubes, an anomalous increase in voltage-gated Ca21
release would be expected when using submaximal KCl
concentrations. Another possible contributing factor is that
our measurements are restricted to rapid voltage-gated
release events obtained at the end of very brief (30-ms)
and uniform voltage steps. By contrast, Yang et al. (2003)
estimated voltage-gated release as the integral of the Ca21
signal in response to much longer (10-s) KCl depolariza-
tions. Additionally, our caffeine-induced Ca21 measure-
ments were obtained at the peak of the response, whereas
Yang et al. (2003) estimated peak caffeine and 4-chloro-m-
cresol responses using a time-integrated method. Differences
in release-channel inactivation, slow myoplasmic Ca21
clearance mechanisms, and/or Ca21 inﬂux pathways could
differentially inﬂuence results obtained using these two
methodologies.
Our results (Fig. 4D) suggest that SRCa21 unloading is not
directly caused by enhanced release-channel activation by
voltage since certain MH-only mutations in RyR1 produced
hyperpolarizing shifts in VF1/2 that were similar to or larger in
magnitude than that observed for someMH1CCDmutations
that promote SR Ca21 depletion (e.g., compare VF1/2 data for
R2163C andR2435L data in Fig. 5D). These ﬁndings suggest
that the increased frequency (R2163H) and prolonged
duration (Y4795C and R2435L) of spontaneous Ca21
oscillations and SR Ca21 depletion (R2163H, Y4785C, and
R2435L) observed for MH 1 CCD mutant release channels
are not directly attributable to increased release-channel
sensitivity to activation by voltage.
Taken together, our results demonstrate that a signiﬁcant
reduction in the magnitude of voltage-gated SR Ca21 release
represents a central distinguishing feature of CCD; either via
decompensated leak and store depletion (Avila and Dirksen,
2001; this study) or by EC uncoupling (Avila et al., 2001,
2003b). Moreover, our results also indicate that RyR1
mutations that result in increased MHS (and not CCD)
produce release-channel defects that promote subtle increases
in release-channel overactivity/sensitivity that occur in the
absence of steady-state store depletion (compensated leak),
whereas MH and CCD coincidence results from mutations
in RyR1 that enhance RyR1 activity/sensitivity to an extent
sufﬁcient to result in partial SR Ca21 store depletion
(decompensated leak). A decade ago, Quane et al. (1993)
suggested that ‘‘a mutation in RyR1 that causes both
hypersensitive gating and diminished excitation-contraction
coupling could cause both MH and CCD in an individual.’’
Our results provide compelling experimental support for this
assertion.
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